公开(公告)号：US20220062408A1

公开(公告)日：2022-03-03

申请号：US17411896

申请日：2021-08-25

Applicant: ModernaTX, Inc.

Inventor： Jack F. Kramarczyk ,  Kimberly Hassett ,  Shinu John ,  Phil White ,  Andrea Carfi

IPC: A61K39/245 ,  C12N7/00

Abstract: Aspects of the disclosure relate to methods for producing an antigen-specific immune response to human cytomegalovirus (hCMV) in a subject by administering mRNA vaccines.

公开(公告)号：US20230142529A1

公开(公告)日：2023-05-11

申请号：US17925114

申请日：2021-05-14

Applicant: ModernaTX, Inc.

Inventor： Philip White ,  Jack F. Kramarczyk ,  Julia O'Neill ,  Nedim Emil Altaras

IPC: C12N15/88 ,  A61K31/713

CPC classification number: C12N15/88 ,  A61K31/713 ,  A61K9/127

Abstract: Present application relates to a strategy for compensating for transesterification degradation of lipid-encapsulated RNA, such as mRNA-LNP, in liquid formulations for high-volume distribution. This involves determining the rate of degradation of the encapsulated RNA and calculating an appropriate overage relative to the intended dose. Alternatively, a higher dose of the RNA may be administered to compensate for loss of effective RNA or the RNA may be formulated in higher purity in anticipation of degradation. The strategy provides a balance between supplying effective and safe products and the need for costly manufacturing processes or transportation hurdles, such as cold-chain supply.

公开(公告)号：US20220401551A1

公开(公告)日：2022-12-22

申请号：US17840478

申请日：2022-06-14

Applicant: ModernaTX, Inc.

Inventor： Jack F. Kramarczyk ,  Kimberly Hassett ,  Shinu John ,  Phil White ,  Andrea Carfi

IPC: A61K39/245 ,  C12N7/00

Abstract: Aspects of the disclosure relate to methods for producing an antigen-specific immune response to human cytomegalovirus (hCMV) in a subject by administering mRNA vaccines.

公开(公告)号：US20230181481A1

公开(公告)日：2023-06-15

申请号：US17925125

申请日：2021-05-14

Applicant: ModernaTX, Inc.

Inventor： Philip White ,  Jack F. Kramarczyk ,  Julia O'Neill ,  Nedim Emil Altaras

IPC: A61K9/51 ,  A61K39/215 ,  A61P31/14

CPC classification number: A61K9/5123 ,  A61K39/215 ,  A61P31/14 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12N2770/20043 ,  C12N2770/20071 ,  A61K2039/53

Abstract: Present application relates to a strategy for compensating for transesterification degradation of lipid-encapsulated SARS-CoV-2 mRNA vaccine, in liquid formulations for high-volume distribution. This involves determining the rate of degradation of the encapsulated RNA and calculating an appropriate overage relative to the intended dose. Alternatively, a higher dose of the RNA may be administered to compensate for loss of effective RNA or the RNA may be formulated in higher purity in anticipation of degradation. The strategy provides a balance between supplying effective and safe products and the need for costly manufacturing processes or transportation hurdles, such as cold-chain supply.

公开(公告)号：US11406703B2

公开(公告)日：2022-08-09

申请号：US17411896

申请日：2021-08-25

Applicant: ModernaTX, Inc.

Inventor： Jack F. Kramarczyk ,  Kimberly Hassett ,  Shinu John ,  Phil White ,  Andrea Carfi

IPC: A61K39/245 ,  C12N7/00 ,  A61K39/00

Abstract: Aspects of the disclosure relate to methods for producing an antigen-specific immune response to human cytomegalovirus (hCMV) in a subject by administering mRNA vaccines.